| Pharmacological treatment of alcohol use disorder in patients with psychotic disorders: A systematic review NJ Rosenstand, AS Nielsen, L Skøt, S Anhøj, DG Nielsen, M Højlund, ... Current Neuropharmacology 22 (6), 1129-1143, 2024 | | 2024 |
| Outcomes in people with eating disorders: a transdiagnostic and disorder‐specific systematic review, meta‐analysis and multivariable meta‐regression analysis M Solmi, F Monaco, M Højlund, AM Monteleone, M Trott, J Firth, ... World Psychiatry 23 (1), 124-138, 2024 | 14 | 2024 |
| Smoking and severe mental illness: Drawing inference on the directionality of the association requires careful consideration of the temporality of the data. MK Lund, M Højlund, LC Lund Wiley-Blackwell Publishing Ltd., 2024 | | 2024 |
| Switching to long-acting injectable antipsychotics: pharmacological considerations and practical approaches M Højlund, CU Correll Expert Opinion on Pharmacotherapy 24 (13), 1463-1489, 2023 | 1 | 2023 |
| Weight gain and metabolic changes in patients with first-episode psychosis or early-phase schizophrenia treated with olanzapine: a meta-analysis CU Correll, M Højlund, C Graham, MS Todtenkopf, D McDonnell, ... International Journal of Neuropsychopharmacology 26 (7), 451-464, 2023 | 7 | 2023 |
| Neonatal and maternal outcomes with elective cesarean section compared to induction of labor in twin pregnancies: A prospective cohort study MH Kjeldsen, M Højlund, E Andreasen, MR Khalil European Journal of Obstetrics & Gynecology and Reproductive Biology 286, 85-89, 2023 | 2 | 2023 |
| The future of child and adolescent clinical psychopharmacology: A systematic review of phase 2, 3, or 4 randomized controlled trials of pharmacologic agents without regulatory … S Cortese, K McGinn, M Højlund, A Apter, C Arango, I Baeza, ... Neuroscience & Biobehavioral Reviews, 105149, 2023 | 5 | 2023 |
| The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de‐risk trial programmes of novel agents CU Correll, M Solmi, S Cortese, M Fava, M Højlund, HC Kraemer, ... World Psychiatry 22 (1), 48-74, 2023 | 55 | 2023 |
| Candidate diagnostic biomarkers for neurodevelopmental disorders in children and adolescents: a systematic review S Cortese, M Solmi, G Michelini, A Bellato, C Blanner, A Canozzi, ... World Psychiatry 22 (1), 129-149, 2023 | 47 | 2023 |
| Response to: The use of low-dose quetiapine does not necessarily increase the risk of major adverse cardiovascular events M Højlund, K Andersen, MT Ernst, CU Correll, J Hallas Acta Neuropsychiatrica 35 (1), 3-4, 2023 | | 2023 |
| Hospitalisation time is associated with weight gain in forensic mental health patients with schizophrenia or bipolar disorder ALW Pedersen, FA Gildberg, P Hjorth, M Højlund, K Andersen Nordic Journal of Psychiatry 77 (1), 46-54, 2023 | 5 | 2023 |
| Use of benzodiazepines and benzodiazepine‐related drugs in the Nordic countries between 2000 and 2020 M Højlund, LS Gudmundsson, JH Andersen, LK Saastamoinen, H Zoega, ... Basic & Clinical Pharmacology & Toxicology 132 (1), 60-70, 2023 | 9 | 2023 |
| Impact of low‐dose quetiapine‐use on glycosylated hemoglobin, triglyceride and cholesterol levels M Højlund, H Støvring, K Andersen, CU Correll, J Hallas Acta Psychiatrica Scandinavica 147 (1), 105-116, 2023 | 6 | 2023 |
| Ulotaront: a TAAR1/5-HT1A agonist in clinical development for the treatment of schizophrenia M Højlund, CU Correll Expert Opinion on Investigational Drugs 31 (12), 1279-1290, 2022 | 8 | 2022 |
| Use of low‐dose quetiapine increases the risk of major adverse cardiovascular events: results from a nationwide active comparator‐controlled cohort study M Højlund, K Andersen, MT Ernst, CU Correll, J Hallas World Psychiatry 21 (3), 444-451, 2022 | 28 | 2022 |
| Free‐of‐charge dispensing of antipsychotics for schizophrenia in Denmark: Impact on the nationwide prescription registry and redemption of somatic medications C Rohde, M Højlund, C Gasse, J Hallas, O Köhler‐Forsberg Basic & Clinical Pharmacology & Toxicology 131 (4), 294-300, 2022 | | 2022 |
| Low-dose Quetiapine: Utilization and Cardiometabolic Risk M Højlund | | 2022 |
| Use of chlorprothixene and the risk of diabetes and major adverse cardiovascular events: A nation-wide cohort study R Wesselhoeft, M Hoejlund, C Wagner, K Andersen, A Fink-Jensen, ... PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 31, 66-66, 2022 | | 2022 |
| Who prescribes quetiapine in Denmark? M Højlund, L Rasmussen, M Olesen, T Munk‐Olsen, A Pottegård British Journal of Clinical Pharmacology 88 (9), 4224-4229, 2022 | 5 | 2022 |
| Lithium and the risk of chronic kidney disease: A population‐based case–control study M Højlund, JS Winkel, M Nybo, J Hallas, DP Henriksen, P Damkier Basic & Clinical Pharmacology & Toxicology 131 (2), 129-137, 2022 | 8 | 2022 |
Christoph Correll; Christoph U CorrellProfessor of Psychiatry and Molecular Medicine, The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Hempstead, NY USA; Professor of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany; Investigator, Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research Manhasset, NY, USA在 northwell.edu 的电子邮件经过验证
